Summit Therapeutics Inc (SMMT)

$11.55

+1.06

(+10.1%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $10.95
    $11.66
    $11.55
    downward going graph

    5.19%

    Downside

    Day's Volatility :6.09%

    Upside

    0.94%

    downward going graph
  • $1.52
    $11.55
    $11.55
    downward going graph

    86.84%

    Downside

    52 Weeks Volatility :86.84%

    Upside

    0.0%

    downward going graph

Returns

PeriodSummit Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
171.76%
6.5%
0.0%
6 Months
170.36%
7.1%
0.0%
1 Year
435.2%
9.8%
0.0%
3 Years
37.48%
14.2%
-20.2%

Highlights

Market Capitalization
7.2B
Book Value
$0.06
Earnings Per Share (EPS)
0.38
PE Ratio
26.84
PEG Ratio
0.0
Wall Street Target Price
10.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-33.27%
Return On Equity TTM
-130.59%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
705.0K
EBITDA
-114.8M
Diluted Eps TTM
0.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.25
EPS Estimate Next Year
-0.29
EPS Estimate Current Quarter
-0.06
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Summit Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
00
Hold
1
1
3
Sell
00
00
3

Analyst Forecast

What analysts predicted

Downside of 7.62%

Current $11.55
Target $10.67

Technicals Summary

Sell

Neutral

Buy

Summit Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Summit Therapeutics Inc
Summit Therapeutics Inc
35.01%
170.36%
435.2%
37.48%
204.94%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Summit Therapeutics Inc
Summit Therapeutics Inc
26.84
26.84
0.0
-0.25
-1.31
-0.33
NA
0.06
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Summit Therapeutics Inc
Summit Therapeutics Inc
Buy
$7.2B
204.94%
26.84
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Summit Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 7 quarters, -14.71M → -43.47M (in $), with an average decrease of 22.6% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 149.0%

Institutional Holdings

  • BlackRock Inc

    1.40%

  • State Street Corporation

    1.16%

  • FMR Inc

    1.14%

  • Vanguard Group Inc

    1.04%

  • Geode Capital Management, LLC

    0.45%

  • Northern Trust Corp

    0.15%

Company Information

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Organization
Summit Therapeutics Inc
Employees
105
CEO
Mr. Robert W. Duggan
Industry
Health Technology

Discover More

FAQs